SCHEMBL724002

SCHEMBL724002

FC(F)Oc1ccc(-c2cc3nccc(-c4cncnc4)c3o2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAT2A P31153 2/20 0.37
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
GSK3A P49840 3/20 0.34
GSK3B P49841 3/20 0.34
F2RL3 Q96RI0 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2A6 P11509 1/20 0.32
BACE1 P56817 1/20 0.32
DYRK1A Q13627 1/20 0.32
HTT P42858 1/20 0.32
MAOB P27338 3/20 0.31
GRM2 Q14416 1/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
MAOA P21397 2/20 0.31
PTGER4 P35408 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL725015 0.89 CYP3A4 (0.42) CYP3A4CYP2C9CYP2C19GSK3AGSK3B
SCHEMBL723095 0.85 MAT2A (0.34) MAT2ACYP3A4CYP2C9CYP2C19GSK3A
SCHEMBL724906 0.84 CYP1A1 (0.35) MAT2ACYP3A4CYP2C9CYP2C19GSK3A
SCHEMBL15216701 0.84 P4HTM (0.35) MAT2ACYP3A4CYP2C9CYP2C19GSK3A
SCHEMBL725071 0.83 CYP3A4 (0.37) MAT2ACYP3A4CYP2C9CYP2C19GSK3A
SCHEMBL723291 0.82 PIK3C3 (0.36) CYP3A4CYP2C9CYP2C19MEN1RAB9A
SCHEMBL722137 0.82 MAT2A (0.45) MAT2AF2RL3CYP2A6NPC1
SCHEMBL725000 0.82 MAT2A (0.36) MAT2ACYP3A4CYP2C9CYP2C19GSK3A
SCHEMBL10267284 0.82 MAOB (0.35) MAT2ACYP3A4CYP2C9CYP2C19GSK3A
SCHEMBL723329 0.81 MAPT (0.39) MAT2AGSK3AGSK3BHTTPTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB MAT2A 4263/4885CYP3A4 2796/4885CYP2C9 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.